Your browser doesn't support javascript.
loading
Achieving Inner Aqueous Drain in Glaucoma Secondary to Iridocorneal Endothelial Syndrome: One Year Results of Penetrating Canaloplasty.
Deng, Yuxuan; Zhang, Shaodan; Ye, Wenqing; Gu, Juan; Lin, Haishuang; Cheng, Huanhuan; Xie, Yanqian; Le, Rongrong; Tao, Yan; Zhang, Wei; Chen, Wei; Tham, Clement C; He, Mingguang; Wang, Ningli; Liang, Yuanbo.
Afiliación
  • Deng Y; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Zhang S; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Ye W; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Gu J; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Lin H; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Cheng H; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Xie Y; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Le R; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Tao Y; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Zhang W; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Chen W; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Tham CC; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • He M; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Wang N; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
  • Liang Y; From National Clinical Research Center for Ocular Diseases, The Eye Hospital of Wenzhou Medical University, Glaucoma Research Institute of Wenzhou Medical University, Zhejiang, China (Y.D, S.Z, W.Y, J.G, H.L, H.C, Y.X, R.L, Y.T, W.C, Y.L);; Qingdao Municipal Hospital, Qingdao, Shandong, China (Y.D);
Am J Ophthalmol ; 243: 83-90, 2022 11.
Article en En | MEDLINE | ID: mdl-35870489
PURPOSES: To report the efficacy of a bleb-independent penetrating canaloplasty in the management of glaucoma secondary to iridocorneal endothelial syndrome (GS-ICE). DESIGN: Prospective, non-comparative clinical study. METHODS: Penetrating canaloplasty was performed on 35 eyes from 35 patients with GS-ICE and medically uncontrolled intraocular pressure (IOP) between January 2018 and April 2020. Patients were followed up at 1 week, months 1, 3, 6, 12 postoperatively, and semi-annually thereafter. The IOP, anti-glaucoma medication, and surgery-related complications were recorded. Surgical success was defined as IOP ≥ 5 mmHg and ≤ 21 mmHg without (complete success) or with/without (qualified success) IOP-lowering medication. RESULTS: A total of 29 eyes (82.9%) had 360° catheterization and successfully received penetrating canaloplasty. Of these eyes, 24 (82.8%) achieved qualified success and 22 (75.9%) achieved qualified success at 12 months after surgery. The mean IOP decreased from 39.5 ± 11.8 mmHg on 2.9 ± 1.0 medications before surgery to 16.6 ± 5.3 mmHg (P < .001) on 0.2 ± 0.6 medications (P < .001) at 12 months postoperatively, respectively. Hyphema (37.9%), transient hypotony (34.5%), and transient postoperative IOP elevation (≥ 30 mmHg, 17.9%) were the most commonly observed early complications at the 1 week and 1 month visits. From 1 month and beyond, all treated eyes showed no obvious bleb at the operation quadrant. CONCLUSIONS: Penetrating canaloplasty rescued the inner aqueous outflow in ICE eyes and demonstrated acceptable success in IOP control with few complications, providing a new option for the management of GS-ICE.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trabeculectomía / Glaucoma / Glaucoma de Ángulo Abierto / Cirugía Filtrante / Síndrome Endotelial Iridocorneal Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Ophthalmol Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Trabeculectomía / Glaucoma / Glaucoma de Ángulo Abierto / Cirugía Filtrante / Síndrome Endotelial Iridocorneal Tipo de estudio: Diagnostic_studies / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Am J Ophthalmol Año: 2022 Tipo del documento: Article